A phase 2 study on efficacy, safety and intratumoral pharmacokinetics of oral selinexor (KPT-330) in patients with recurrent glioblastoma (GBM)

Authors :: Greg Wright
Patrick Y. Wen
Morten Mau-Sørensen
Aleksander Chudnovsky
Sharon Friedlander
Andrew B. Lassman
Andrew L. Kung
Joel Ellis
Bert van Eijk
Sharon Shacham
Michael Kauffman
Scott R. Plotkin
Ulrik Lassen
Jean-Richard Saint-Martin
Source :: Journal of Clinical Oncology. 34:2077-2077
Publication Year :: 2016
Publisher :: American Society of Clinical Oncology (ASCO), 2016.
Abstract: 2044 Background: Patients (pts) with recurrent GBM have few treatment options and a poor prognosis. Selinexor is an oral inhibitor of XPO1 mediated nuclear export resulting in nuclear retention of ...

Subjects :: Oncology
Cancer Research
Poor prognosis
Pathology
medicine.medical_specialty
business.industry
Recurrent glioblastoma
Treatment options
Phases of clinical research
stomatognathic diseases
Pharmacokinetics
Internal medicine
Medicine
In patient
business

Full Text Access

Tools